This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent. Top assignee: Biontech Se. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Rodney Gene Combs: Innovator in In Vitro Transcription Technologies
Introduction
Rodney Gene Combs is a notable inventor based in Wildwood, MO (US). He has made significant contributions to the field of biotechnology, particularly in the area of in vitro transcription technologies. His work focuses on the production of pharmaceutical-grade RNA, which is essential for various medical applications.
Latest Patents
Rodney holds 1 patent related to in vitro transcription technologies. This patent provides innovative methods for conducting in vitro transcription reactions, especially aimed at large-scale production of RNA. His advancements in this area have the potential to enhance the efficiency and quality of RNA production for pharmaceutical purposes.
Career Highlights
Throughout his career, Rodney has worked with prominent companies in the biotechnology sector. Notably, he has been associated with BioNTech SE and VTV Therapeutics LLC. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the field.
Collaborations
Rodney has collaborated with talented professionals, including Irena Rabe and Maximilian Buff. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Rodney Gene Combs is a distinguished inventor whose work in in vitro transcription technologies is paving the way for advancements in pharmaceutical RNA production. His contributions to the field are invaluable and continue to influence the biotechnology landscape.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile